الفهرس Only 14 pages are availabe for public view
 |  | from | 230 |  |  |
| | | from | 230 | | |
Abstract
The hepatitis C virus (HCV), the main cause of morbidity and mortality, is endemic worldwide. HCV is most common in underdeveloped nations, with the highest prevalence rates in Egypt. The dual therapy with pegylated-interferon - Ü2b plus ribavirin has markedly improved the clinical outcome of HCV. P53 induces the expression of Fas for triggering apoptosis; an important mechanism for limiting viral replication. This study aims at investigating the impact of P53 rs 1042522 and Fas rs 1800682 genetic polymorphisms at 72 Arg / Pro and -670 A / G respectively on HCV genotype - 4a susceptibility and treatment response. Two hundred and forty volunteers were enrolled in this study and divided into two major groups; the first group was 160 HCV infected patients group and the second group was 80 healthy controls group. HCV patients were sub-divided into two sub - groups; 86 sustained virological responders sub - group and 74 non-responders sub - group